Cost-utility analysis of acupotomy combined with epidural steroid injection for lumbosacral radiculopathy: analysis of randomized controlled trial Authors: Semin Jang, Tae-Yong Park, Jin-Hyun Lee, Hae Sun Suh Published: 2025 ABSTRACT BackgroundLumbosacral radiculopathy, characterized by lower back nerve root pain, is a leading cause of activity limitations and healthcare costs. Acupotomy is a combination of acupuncture and minimally invasive treatment that relieves soft-tissue adhesions, complementing the anti-inflammatory effect of epidural steroid injection (ESI). Although the combination of acupotomy and ESI has shown clinical evidence for pain management, economic evaluations remain scarce. To address this gap, we performed a cost-utility analysis comparing Acupotomy combined with ESI and ESI alone in patients with lumbosacral radiculopathy.MethodsA randomized controlled trial enrolled patients aged 18–85 years with lumbosacral radiculopathy. Participants were randomized 1:1 to receive either Acupotomy with ESI or ESI single treatment. Utility values were measured using the EuroQol-5 Dimensions-5 Levels questionnaire, and quality-adjusted life year (QALY) were calculated. Direct (medical and non-medical) and indirect costs (productivity loss) were estimated from a societal perspective. The incremental cost-utility ratio was calculated to evaluate the cost-effectiveness of the interventions.ResultsAmong 50 patients, the mean age was 62.0 years, and 58.0% were females. The overall costs, including direct and indirect costs, were $609 for the Acupotomy with ESI group and $757 for the ESI group. The incremental QALYs for the Acupotomy with ESI group compared to the ESI group were 0.01 QALYs, and the incremental costs were -$147. The incremental cost-utility ratio was -$16,314/QALY, indicating the dominance of combination therapy. Additionally, the average indirect costs for the Acupotomy with ESI and the ESI group were $243 and $498, respectively, representing lower indirect costs in combination therapy.ConclusionsAcupotomy with ESI treatment was associated with short-term improvements in quality of life and lower total costs over 8 weeks, compared to ESI. These findings should be interpreted with caution, given the limited sample size, short follow-up period, and the restricted generalizability due to a single-center design and specific clinical setting. Nonetheless, this study provides preliminary evidence suggesting the potential cost-effectiveness of acupotomy with ESI for managing lumbosacral radiculopathy.Trial registrationtrial registration number, KCT0006158.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12906-025-05212-2. Background Low back pain continues to represent one of the most prevalent and disabling conditions worldwide, with an estimated 619 million people affected in 2020 [1]. It also imposes a significant economic burden, particularly in high-income countries [2]. Among individuals with low back pain, only 5% to 10% suffer from lumbosacral radiculopathy, a condition caused by compression or irritation of the lumbar nerve roots [3–5]. This condition is characterized by radiating pain from the lower back down to the legs, often extending below the knee and into the foot [3, 6]. Lumbosacral radiculopathy has been reported to have a lifetime prevalence of 40–90% and an annual incidence of 2.2% in the general population [7–9]. In South Korea, National Health Insurance Service claims analyses showed a 30% growth in patients receiving nonsurgical management and an absolute increase in direct medical expenditures of over USD 2 million for lumbar disc herniation with radiculopathy over the past decade, highlighting a rising economic burden [10]. Standard non-surgical treatments for lumbosacral radiculopathy generally involves pharmacological and physical therapies such as non-steroidal anti-inflammatory drugs (NSAIDs), exercise programs, corticosteroids, and epidural steroid injections (ESI) [11]. ESI, a nonsurgical, minimally invasive treatment, is a preferred option to manage lumbosacral radiculopathy [12]. For cases unresponsive to conservative management, surgical options such as open laminectomy with discectomy could be considered. However, Acupotomy, a modern therapeutic intervention combining elements of traditional acupuncture and minor surgical techniques, has gained wider clinical use in Korea and China as a promising treatment for musculoskeletal pain [13, 14]. It has also been considered a minimally invasive option for patients suffering from lumbosacral radiculopathy [15, 16]. Accordingly, the Korean clinical practice guideline for lumbar disc herniation recommends considering acupotomy as an adjunctive treatment when symptoms persist or worsen [17]. Transforaminal ESI reduces nerve-root inflammation and provides short-term pain relief in lumbosacral radiculopathy [18], whereas acupotomy is intended to mechanically release fibrotic adhesions. These complementary biochemical (ESI) and mechanical (acupotomy) actions provide a plausible basis for synergy when symptoms persist despite standard care. Recent evidence supports its clinical effectiveness: a randomized controlled trial in patients with lumbosacral radiculopathy reported significant pain reduction [19], and a subsequent systematic review and network meta-analysis further demonstrated that acupotomy combined with ESI effectively relieves pain [20]. Despite emerging data, trial-based cost-utility evidence or economic impact of acupotomy is scarce, particularly in the Korean context, highlighting the need for this study. Adding acupotomy to transforaminal ESI increases extra resources beyond ESI alone. We assessed whether any health-related quality of life (HRQoL) gains justify the added costs using a cost-utility analysis. This study aims to evaluate the cost-effectiveness of Acupotomy combined with ESI versus ESI single treatment in patients with lumbosacral radiculopathy. A cost-utility analysis was conducted through a randomized controlled trial, assessing both direct and indirect costs, as well as quality-adjusted life years (QALYs), to determine the societal impact of these interventions. Methods Study design and participants This cost-utility analysis was conducted in the open-label, parallel, assessor-blinded randomized controlled trial (RCT) [19], and was conducted at Catholic Kwandong University International St. Mary’s Hospital, Incheon, South Korea (trial registration number: KCT0006158, Registered on May 11, 2021). Details of the study protocol, trial procedures, and primary outcomes were publsihed by Lee et al. (2024) [19, 21]. The trial included patients with severe lumbosacral radiculopathy who showed insufficient improvement after nerve block therapy. Eligible participants were aged 18 to 85 years, diagnosed with lumbosacral intervertebral disc disorder, spinal stenosis, or radiculopathy within 6 months prior to the trial, and had symptoms related to lumbosacral radiculopathy with a Numerical Rating Scale score higher than 5. Exclusion criteria included a history of spinal surgery within the past 6 months, ongoing surgical procedures, active medication treatment, or Acupotomy treatment within 2 weeks before the trial [19]. Participants were randomly assigned to either the control group, receiving ESI single-treatment, or the experimental group, receiving a combination of Acupotomy with ESI. In the combination group, participants received a total of 10 treatment visits (8 acupotomy sessions and 2 ESI sessions), wheras the ESI-single treatment group received 2 ESI sessions. This disparity in treatment frequency was considered when analyzing direct and indirect costs. The sample size was 50 participants (25 per group). Since no prior research has reported QALY-based effects of acupotomy in lumbosacral radiculopathy, the sample size was determined based on feasibility considerations and by referencing previous randomized trials of acupotomy for lumbar conditions [14, 22]. The study was conducted by the Declaration of Helsinki and was reviewed and approved by the institutional review board of Catholic Kwandong University, International St. Mary’s Hospital (Registration number: IS20OISE0085 on 11 January 2021). Intervention Both groups received ESI twice, administered once a week. Acupotomy was additionally performed in the experimental group. ESI was performed in the pain clinic of a Korean secondary hospital by anesthesiologists. Acupotomy, a technique that combines acupuncture and micro-invasive treatment, was applied to the location of the Hyeopcheok point, which is clearly described in previous references, including the protocol and research demonstrating clinical outcomes of this RCT [15, 19, 21]. The anatomical location of the Hyupcheok point corresponds to the acupuncture point EX-B2 and is medically comparable to the location of the lumbar facet joint (Supplementary Fig. 1). Acupotomy treatments were provided twice a week for four weeks, for a total of eight sessions. All procedures were performed by licensed Korean medicine doctors holding the Korean Medicine Rehabilitation Medicine Specialist certification and having more than 10 years of clinical experience. Each procedure was conducted according to a standardized operating protocol under aseptic conditions, with a registered nurse providing assistance with pre- and post-procedure care. During the stupdy period, participants did not receive any additional treatments such as physiotherapy, additional injections, or nerve block therapies. Full procedural details of both interventions were described in previously published protocol and trial reports [19, 21]. Health-related quality of life We derived QALYs as the outcome of HRQoL. QALYs were estimated by weighting each time period according to health-state utilities, where 0 represents death and 1 represents perfect health, such that higher values indicate better HRQoL. Utilities were assessed using the Korean version of the EuroQol-5 Dimensions-5 Levels (EQ-5D-5 L) and were converted to utilities using the Korean value set (tariff) [23]. Utilities were measured at baseline (week 0), week 2, week 4, and week 8. Total QALYs over 8 weeks were calculated as the area under the utility-time curve (Fig. 1) [24]. To reflect morbidity during the study, adverse event-related disutilities were applied for the duration of each event so that estimated QALYs captured the temporary decrement in HRQoL. Fig. 1The area under the curve approach of quality-adjusted life years over 8 weeks The area under the curve approach of quality-adjusted life years over 8 weeks Cost Costs were evaluated from both societal and healthcare system perspectives through micro-costing approach based on patient-level survey data. We included direct costs (medical and non-medical) and indirect costs (productivity loss), collected in week 0 (baseline), week 2, week 4, and week 8. Medical costs included intervention-related expenses and other healthcare services. Non-medical costs included patient time costs, transportation-, and caregiving expenses. Indirect costs were assessed as productivity loss using the validated iMTA Productivity Cost Questionnaire, which assessed absenteeism, presenteeism, and loss of unpaid work [25, 26]. Patient-level costs were obtained using a structured questionnaire adapted from the National Evidence-based healthcare Collaborating Agency’s cost-effectiveness guideline [27]. To minimize recall error and enhance internal consistency, we implemented a written standard operating procedure (SOP), standardized scripts and training for clinical research coordinators, real-time query resolution. Participants were encouraged to bring receipts to substantiate out-of-pocket payments, and costs were collected at each study visit for the period from the previous contact. All costs were converted to U.S. Dollars (USD) using the 2022 exchange rate (1 USD = 1,294 KRW). Detailed methods for cost calculations and cost survey questionnaire are provided in Supplementary Table 1, Supplementary Material 1, respectively. Incremental cost-utility ratio We derived the incremental cost-utility ratio (ICUR) as the outcome of cost-utility analysis, which was calculated by dividing the incremental cost by the incremental QALYs from ESI and Acupotomy with ESI groups (Formula 1). Formula 1. Incremental cost-utility ratio formula\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\begin{aligned} \:ICUR&=\frac{{Cost}_{Acupotomy\:with\:ESI}-\:{Cost}_{ESI}}{{QALY}_{Acupotomy\:with\:ESI}-\:{QALY}_{ESI}}\\&=\frac{{\Delta\:}Costs}{{\Delta\:}QALYs\:gained}\end{aligned}$$\end{document} ESI, epidural steroid injection; ICUR, incremental cost-utility ratio; QALYs, quality-adjusted life-years. Sensitivity analysis We conducted a probabilistic sensitivity analysis (PSA) to assess the uncertainties of the results. Costs and QALYs were modeled with a gamma distribution, and 1,000 iterations were performed. The results are presented as scatter plots and cost-effectiveness acceptability curves (CEAC) with a willingness-to-pay (WTP) threshold of $32,395, based on South Korea’s 2022 gross domestic product per capita. ICUR below the WTP threshold is indicated as cost-effective [28]. Statistical analysis The analysis was conducted on an intention-to-treat population. Missing values were imputed using the baseline observation carried forward method. Descriptive statistics were used to summarize the data: categorical variables were reported as frequencies and percentages, while continuous variables were presented as means, standard deviations (SD), and 95% confidence intervals (CI). An independent t-test was performed to compare the value of the score of EQ-5D-5 L, with statistical significance defined as p < 0.05. With 25 participants per group, the study had approximately 80% power to detect a large, standardized difference but was underpowered to detect smaller effects. All statistical analyses were performed using Microsoft Excel Office 365. Results Baseline characteristics A total of 50 participants were enrolled in this trial, with 25 individuals assigned to each treatment group: the ESI group and the Acupotomy with ESI group. At baseline, the mean ages were 63.2 years and 60.8 years, respectively. The proportion of females was higher in the Acupotomy with ESI group at 60.8%. Groups appeared similar on most baseline characteristics, except for comorbidities and income, which may reflect baseline imbalance despite randomization (Table 1). No significant differences were observed between the two groups, indicating comparable baseline characteristics (Table 1). Table 1Demographic characteristicsESI groupAcupotomywith ESI groupSample size, n2525Female gender, n (%)12 (48)17 (68)Mean age, year (SD)63.2 (10.7)60.8 (13.1)Height, cm (SD)161.3 (8.6)159.4 (9.4)Weight, kg (SD)64.9 (12.1)62.9 (14.8)BMI, kg/m2 (SD)24.8 (3.8)24.4 (3.6)Occupation status, n (%) Yes16 (64)14 (56)Marital status, n (%) Married17 (68)18 (72) Divorced7 (28)6 (24) Non-married0 (0)1 (4)Education level, n (%) Elementary school grad.7 (28)5 (20) Middle school grad.5 (20)6 (24) High school grad.5 (20)9 (36) College grad.4 (16)4 (16) University grad.4 (16)1 (4)Monthly household income, n (%) <$3,00015 (60)18 (72) $3,000-$7,0006 (24)6 (24) >$7,0004 (16)1 (4)Comorbidities, n (%) Hypertention9 (36)4 (16) Osteoporosis3 (12)2 (8) Dyslipidemia8 (32)5 (20)Granular diagnostic/pathology variables and comorbidity severity were not systematically recorded. Baseline characteristics are presented descriptively, without statistical testsBMI Body mass index, ESI Epidural steroids injection, SD Standard deviation Table 1Demographic characteristicsESI groupAcupotomywith ESI groupSample size, n2525Female gender, n (%)12 (48)17 (68)Mean age, year (SD)63.2 (10.7)60.8 (13.1)Height, cm (SD)161.3 (8.6)159.4 (9.4)Weight, kg (SD)64.9 (12.1)62.9 (14.8)BMI, kg/m2 (SD)24.8 (3.8)24.4 (3.6)Occupation status, n (%) Yes16 (64)14 (56)Marital status, n (%) Married17 (68)18 (72) Divorced7 (28)6 (24) Non-married0 (0)1 (4)Education level, n (%) Elementary school grad.7 (28)5 (20) Middle school grad.5 (20)6 (24) High school grad.5 (20)9 (36) College grad.4 (16)4 (16) University grad.4 (16)1 (4)Monthly household income, n (%) <$3,00015 (60)18 (72) $3,000-$7,0006 (24)6 (24) >$7,0004 (16)1 (4)Comorbidities, n (%) Hypertention9 (36)4 (16) Osteoporosis3 (12)2 (8) Dyslipidemia8 (32)5 (20)Granular diagnostic/pathology variables and comorbidity severity were not systematically recorded. Baseline characteristics are presented descriptively, without statistical testsBMI Body mass index, ESI Epidural steroids injection, SD Standard deviation Demographic characteristics Granular diagnostic/pathology variables and comorbidity severity were not systematically recorded. Baseline characteristics are presented descriptively, without statistical tests BMI Body mass index, ESI Epidural steroids injection, SD Standard deviation Health-related quality of life At week 0, the mean utility values were 0.63 for the ESI group and 0.58 for the combination group, with no significant difference (p = 0.27) (Table 2). By week 4, the Acupotomy with ESI group showed greater improvement in utility compared to the ESI group (p = 0.03). At week 8, the Acupotomy with ESI group maintained higher utility scores than the ESI group, with a borderline statistical difference (p = 0.05). QALYs over 8 weeks were 0.10 for the ESI group and 0.11 for the Acupotomy with ESI group, reflecting the greater utility improvement in the latter. Table 2EQ-5D-5 L utility value and 8-week QALYsESI group(N = 25)Acupotomy with ESI group (N = 25)P-value*Visit timepointsMean (SD)95% CIMean (SD)95% CIWeek 0 (Baseline)0.63 (0.14)0.57, 0.680.58 (0.17)0.51, 0.640.27Week 20.65 (0.15)0.59, 0.710.73 (0.17)0.67, 0.790.06Week 40.67 (0.16)0.61, 0.730.77 (0.15)0.71, 0.830.03Week 80.71 (0.14)0.54, 0.770.78 (0.11)0.74, 0.820.05CI Confidence interval, ESI Epidural steroids injection, EQ-5D-5L EuroQol-5 Dimensions-5 Levels, QALY Quality-adjusted life year, SD Standard deviation*P-values are based on independent t-tests with equal variances Table 2EQ-5D-5 L utility value and 8-week QALYsESI group(N = 25)Acupotomy with ESI group (N = 25)P-value*Visit timepointsMean (SD)95% CIMean (SD)95% CIWeek 0 (Baseline)0.63 (0.14)0.57, 0.680.58 (0.17)0.51, 0.640.27Week 20.65 (0.15)0.59, 0.710.73 (0.17)0.67, 0.790.06Week 40.67 (0.16)0.61, 0.730.77 (0.15)0.71, 0.830.03Week 80.71 (0.14)0.54, 0.770.78 (0.11)0.74, 0.820.05CI Confidence interval, ESI Epidural steroids injection, EQ-5D-5L EuroQol-5 Dimensions-5 Levels, QALY Quality-adjusted life year, SD Standard deviation*P-values are based on independent t-tests with equal variances EQ-5D-5 L utility value and 8-week QALYs CI Confidence interval, ESI Epidural steroids injection, EQ-5D-5L EuroQol-5 Dimensions-5 Levels, QALY Quality-adjusted life year, SD Standard deviation *P-values are based on independent t-tests with equal variances Costs Table 3 provides a comparison of the average costs per patient between the ESI group and the Acupotomy with ESI group. Formal medical costs were higher in the Acupotomy with ESI group ($306.35) than in the ESI group ($227.63), due to the greater number of treatment visits compared to the ESI group. However, despite more visits, the combination group demonstrated lower total costs, particularly driven by reduced productivity loss and non-medical costs. From the healthcare system perspective, total costs were slightly higher in the Acupotomy with ESI group (Acupotomy with ESI, $308; ESI $228). From the societal perspective, the total costs were lower in the Acupotomy and ESI group despite higher direct medical costs. The overall savings were generated from a reduction in indirect costs (Acupotomy with ESI, $609; ESI, $757). Table 3Average costs per patient by treatment groupsESI group(N = 25)Acupotomy with ESI group (N = 25) Direct costs Medical costs (SD) Formal costs$227.63 (102.36)$306.35 (73.84) Informal costs$0.12 (0.62)$1.45 (6.02) Non-medical costs$30.51 (20.49)$58.61 (28.02) Indirect costs Productivity loss costs (SD)$498.35 (898.63)$243.07 (523.03)Total costsa Healthcare system perspectiveb$227.76$307.79 Societal perspectivec$756.62$609.48aTotal cost did not include the cost accounted at the baseline time pointbThe healthcare system perspective includes the formal and informal medical costcThe societal perspective includes formal cost, informal cost, non-medical cost, and productivity loss costESI Epidural steroid injection, SD Standard deviation Table 3Average costs per patient by treatment groupsESI group(N = 25)Acupotomy with ESI group (N = 25) Direct costs Medical costs (SD) Formal costs$227.63 (102.36)$306.35 (73.84) Informal costs$0.12 (0.62)$1.45 (6.02) Non-medical costs$30.51 (20.49)$58.61 (28.02) Indirect costs Productivity loss costs (SD)$498.35 (898.63)$243.07 (523.03)Total costsa Healthcare system perspectiveb$227.76$307.79 Societal perspectivec$756.62$609.48aTotal cost did not include the cost accounted at the baseline time pointbThe healthcare system perspective includes the formal and informal medical costcThe societal perspective includes formal cost, informal cost, non-medical cost, and productivity loss costESI Epidural steroid injection, SD Standard deviation Average costs per patient by treatment groups aTotal cost did not include the cost accounted at the baseline time point bThe healthcare system perspective includes the formal and informal medical cost cThe societal perspective includes formal cost, informal cost, non-medical cost, and productivity loss cost ESI Epidural steroid injection, SD Standard deviation Figure 2 presents the average indirect costs for the ESI group and the Acupotomy with ESI group at four timepoints: week 0, week 2, week 4, and week 8. At week 0, both groups exhibited similar costs, but the Acupotomy with ESI group demonstrated a greater and more sustained cost reduction over the following weeks. By week 8, the ESI group showed an increase in indirect costs, while the Acupotomy with ESI group maintained consistently lower costs throughout the remaining timepoints. Fig. 2Comparison of average productivity loss costs over time by treatment groups Comparison of average productivity loss costs over time by treatment groups Cost-utility analysis Table 4 presents the results of a cost-utility analysis comparing Acupotomy with ESI to ESI alone. The Acupotomy with ESI group achieved slightly higher QALY (0.11) than the ESI group (0.10), with an incremental QALY gain of 0.01. From the healthcare system perspective, the incremental cost of Acupotomy with ESI was $80.04, resulting in an ICUR of $8,873.93 per QALY gained. From the societal perspective, Acupotomy with ESI resulted in cost savings of $147.14, yielding a negative ICUR of -$16,313.67 per QALY gained, suggesting the dominance of Acupotomy with ESI combination therapy. Table 4Results of cost-utility analysis of acupotomy with ESI compared to the ESI groupESI groupAcupotomywith ESI groupIncrementalQALYs*0.100.110.01Costs Healthcare system perspective$227.76$307.79$80.04 Societal perspective$756.62$609.48-$147.14ICUR ($/QALYs) Healthcare system perspective8873.93 Societal perspective-16313.67ESI Epidural steroid injection, ICUR Incremental cost-utility ratio, QALY Quality-adjusted life year*8 weeks of QALY were estimated. QALYs were calculated over 8 weeks using a model that accounts for disutility from adverse events Table 4Results of cost-utility analysis of acupotomy with ESI compared to the ESI groupESI groupAcupotomywith ESI groupIncrementalQALYs*0.100.110.01Costs Healthcare system perspective$227.76$307.79$80.04 Societal perspective$756.62$609.48-$147.14ICUR ($/QALYs) Healthcare system perspective8873.93 Societal perspective-16313.67ESI Epidural steroid injection, ICUR Incremental cost-utility ratio, QALY Quality-adjusted life year*8 weeks of QALY were estimated. QALYs were calculated over 8 weeks using a model that accounts for disutility from adverse events Results of cost-utility analysis of acupotomy with ESI compared to the ESI group ESI Epidural steroid injection, ICUR Incremental cost-utility ratio, QALY Quality-adjusted life year *8 weeks of QALY were estimated. QALYs were calculated over 8 weeks using a model that accounts for disutility from adverse events Sensitivity analysis The PSA results of 1,000 iterations were presented in Fig. 3. The probability that Acupotomy with ESI treatment is cost-effective is 92.4% and 93.5%, in the healthcare system and societal perspective, respectively, at the WTP threshold (Fig. 3). In CEAC, Acupotomy with ESI treatment was indicated as more cost-effective than ESI alone in both perspectives (Fig. 4). Fig. 3Scatter plot of incremental cost-utility ratio perspective; (a) healthcare system perspective, (b) societal perspective Scatter plot of incremental cost-utility ratio perspective; (a) healthcare system perspective, (b) societal perspective Fig. 4Cost-effectiveness acceptability curve by perspective; (a) healthcare system perspective, (b) societal perspective Cost-effectiveness acceptability curve by perspective; (a) healthcare system perspective, (b) societal perspective Discussion To our knowledge, this is the first published trial analyzing the cost-effectiveness of Acupotomy for lumbosacral radiculopathy. This study assessed the cost-effectiveness of combining Acupotomy with ESI for lumbosacral radiculopathy. Using ESI as the standard treatment, we evaluated whether the addition of Acupotomy could enhance both clinical outcomes and economic efficiency. The results indicated that the combined treatment improves quality of life and reduces total direct medical costs. While both groups were comparable at baseline, by week 4 to 8, the Acupotomy with the ESI group showed improvements in utility scores, with slightly higher QALYs compared to the ESI group. While direct medical costs were higher for the Acupotomy group, reductions in productivity loss resulted in overall cost savings from a societal perspective, underscoring the economic advantages of this combined treatment. For PSA, the bootstrapped ICER results indicated that the combination therapy was generally more effective and less costly, with most estimates falling below the willingness-to-pay, thereby supporting the robustness of the base-case findings. However, these findings should be interpreted with caution, given the short 8-week follow-up, which limits conclusions regarding long-term clinical and economic outcomes. There is no established threshold for a clinically meaningful QALY difference in lumbosacral radiculopathy. Based on prior research, Walter et al. (2025) reported an average minimally important difference of EQ-5D of 0.074 across various disease conditions, which translates to approximately 0.011 QALYs over our 8-week horizon [29]. The between-group difference in our study (0.01 QALYs) might be comparable to this reference value, but should be interpreted with caution, given the small sample size and borderline p-values. Furthermore, when examining the cost components, the Acupotomy with ESI group showed higher direct medical costs due to the greater number of treatment visits, but overall societal costs were lower because of reduced productivity loss. Therefore, the observed cost savings were primarily driven by reductions in indirect costs, consistent with improvements in HRQoL. Besides, in clinical practice, acupotomy requires trained practitioners and appropriate equipment. In this trial, all procedures were delivered by certified specialists with more than 10 years of experience, following standardized protocol. Broader implementation may vary according to practitioner availability, training and credentialing systems, regulatory frameworks, and adoption across health systems. Our findings are generated within the Korean healthcare context and may not directly generalize to Western settings. Clinical pathways and co-interventions (e.g., physiotherapy, chiropractic, analgesic regimens) could alter, thereby changing incremental costs and QALYs. Moreover, the country-specific EQ-5D tariffs, unit prices, and WTP threshold may yield different ICER. To date, studies using Acupotomy as an intervention for lumbosacral radiculopathy are scarce, with no available cost-effectiveness analyses. Previous research includes case reports (n = 7) [30] and retrospective studies (n = 20) [31], which assessed changes in the Numerical Rating Scale, and the Oswestry Disability Index before and after Acupotomy in lumbar herniated disc patients. However, these studies did not include control groups and instead involved Acupotomy alongside other treatments such as acupuncture, medication, and physical therapy, which may have made it challenging to fully attribute the outcomes to Acupotomy alone. RCT comparing Acupotomy and manual acupuncture has shown promising results. Kim et al. (2018) (n = 50) reported higher post-treatment EQ-5D scores in the Acupotomy group compared to manual acupuncture [14], while Jeong et al. (n = 146) found that although point estimates of EQ-5D scores were higher in the Acupotomy group, there was no statistically significant difference between the groups [16]. Both studies indicated that Acupotomy was effective in pain reduction, but neither performed cost-effectiveness analyses, leaving the economic benefits of Acupotomy unexplored. However, Kim et al. conducted a secondary analysis using cost-effectiveness analysis to compare non-pharmacological treatments (acupuncture, Chuna manual therapy, and electroacupuncture) with pharmacological treatments (physical therapy, prescriptions, and nerve blocks) for patients with lumbar disc herniation [32]. While no significant differences were found in clinical outcomes, the non-pharmacological group was more cost-effective. However, in alignment with real clinical practice, the pharmacological group was allowed to receive additional physical therapies as needed, which may have complicated the ability to isolate the genuine effect of non-pharmacological treatments. Similarly, Sung et al. evaluated the cost-effectiveness of thread-embedding acupuncture combined with traditional acupuncture versus traditional acupuncture alone in chronic low back pain patients [33]. Although the combination therapy improved clinical outcomes, the cost-effectiveness analysis did not show significant differences, and the absence of an incremental cost-effectiveness ratio, sensitivity analysis, and QALY estimation methods raised concerns about the robustness of the results. Additionally, indirect costs were not included, leaving societal cost-effectiveness underexplored. This study has several strengths. First, it is the first to compare the cost-effectiveness and cost-utility of ESI alone versus the combination of Acupotomy and ESI, offering valuable insights into the synergistic effects of integrating Western and Korean medical treatments. Second, we adopted a societal perspective, including indirect costs, to fully capture the broader economic impact of lumbosacral radiculopathy. Third, we accounted for disutility by incorporating adverse event-related utility when calculating QALYs, ensuring conservative and reliable outcomes. Finally, the sensitivity analysis confirmed the robustness of our findings. However, this study has some limitations. First, given the small sample size, the findings should be interpreted with caution, and larger multicenter studies are needed to confirm the clinical and economic implications of acupotomy with ESI. Besides, although randomization was applied, the small sample size may have allowed undetected baseline imbalances. Descriptive differences were observed in comorbidities and income, which could have influenced outcomes. Second, the relatively short follow-up duration of 8 weeks may not be sufficient to assess the long-term cost-effectiveness of the intervention. This duration was chosen to reflect real-world clinical practice in Korea, where ESI is typically administered every 2 weeks for three sessions, often with additional acupotomy. While this pragmatic design reflects real-world practice, the short duration still limits conclusions on long-term outcomes. Given that lumbosacral radiculopathy is a chronic condition and that the cost-effectiveness of interventions may change over time as recurrences, productivity loss, or sustained improvements accumulate, future studies with extended follow-up periods of at least 12 months are warranted. Third, direct costs were collected through one-on-one surveys with patients and clinical research coordinators, relying on patient recall, which could introduce recall bias. Unfortunately, publicly available data on oriental treatment-related costs is limited, making this the best available dataset. Although due to the trial design, the Acupotomy with ESI group had 8 more visits, potentially leading to an overestimation of medical costs, the results showed cost-effectiveness and were conservative. Fourth, the disparity in treatment visits between groups which inevitably increased direct medical costs in the combination group. However, the reduced productivity loss and non-medical costs offset these costs, leading to overall cost savings. This difference in visit frequency should be considered when interpreting the cost comparison. Fifth, the single-center design and system-level differences may limit the generalizability. This trial was conducted in a Korean secondary hospital, and the integration of acupotomy with ESI reflects the Korean healthcare system, where Korean medicine services are integrated with conventional care. Practitioner availability, regulatory frameworks, and reimbursement policies may vary across health systems, which could influence the implementation and generalizability of acupotomy in other settings. Sixth, the self-reported costs survey contains recall bias. However, we followed a strictly constructed SOP, real-time query resolution, and encouraged patients to reference receipts of out-of-pocket payments. Seventh, there is a possibility of residual confounding. Given the small sample size, undetected baseline imbalances may exist despite randomization. In addition, detailed diagnostic information and comorbidity severity were not collected, which further limits our ability to assess comparability between groups. These factors may have influenced outcomes and costs, underscoring the need for larger multicenter trials with standardized baseline characterization. Conclusions This study confirms the cost-effectiveness of combination therapy, Acupotomy with ESI, that is already in practical use for non-surgical management of lumbosacral radiculopathy. Furthermore, these cost-utility analysis results could provide valuable evidence to support the recognition of Acupotomy as a new health technology in the Korean medicine field. Supplementary Information Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2.